Articles: disease.
-
Pol. Arch. Med. Wewn. · Mar 2023
Multiple drug intolerance in patients with arterial hypertension: prevalence and determining factors.
One of the reasons for poor medication compliance among patients is the occurrence of adverse drug reactions. ⋯ MDIS in patients with hypertension is common and more frequently affects women and patients with a longer known disease duration. Comorbidities increase the risk of MDIS. Its risk is strongly associated with the use of analgesics, β‑blockers, antiplatelet drugs, and antibiotics.
-
Randomized Controlled Trial Multicenter Study
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase 2 study in patients with systemic lupus erythematosus (SLE), baricitinib 4 mg significantly improved SLE disease activity compared with placebo. The objective of this trial was to evaluate the efficacy and safety of baricitinib in patients with active SLE in a 52-week phase 3 study. ⋯ Eli Lilly and Company.